254 related articles for article (PubMed ID: 33174532)
21. Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice.
Rodriguez-Alvarez N; Jimenez-Mateos EM; Engel T; Quinlan S; Reschke CR; Conroy RM; Bhattacharya A; Boylan GB; Henshall DC
Neuropharmacology; 2017 Apr; 116():351-363. PubMed ID: 28082183
[TBL] [Abstract][Full Text] [Related]
22. Autophagy activation and neuroprotection by progesterone in the G93A-SOD1 transgenic mouse model of amyotrophic lateral sclerosis.
Kim J; Kim TY; Cho KS; Kim HN; Koh JY
Neurobiol Dis; 2013 Nov; 59():80-5. PubMed ID: 23891729
[TBL] [Abstract][Full Text] [Related]
23. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model.
Li Y; Guo Y; Wang X; Yu X; Duan W; Hong K; Wang J; Han H; Li C
Neuroscience; 2015 Jul; 298():12-25. PubMed ID: 25841320
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
[TBL] [Abstract][Full Text] [Related]
25. In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1
Bonifacino T; Cattaneo L; Gallia E; Puliti A; Melone M; Provenzano F; Bossi S; Musante I; Usai C; Conti F; Bonanno G; Milanese M
Neuropharmacology; 2017 Sep; 123():433-445. PubMed ID: 28645622
[TBL] [Abstract][Full Text] [Related]
26. Pleiotropic activity of systemically delivered angiogenin in the SOD1
Crivello M; O'Riordan SL; Woods I; Cannon S; Halang L; Coughlan KS; Hogg MC; Lewandowski SA; Prehn JHM
Neuropharmacology; 2018 May; 133():503-511. PubMed ID: 29486168
[TBL] [Abstract][Full Text] [Related]
27. Compensatory changes in degenerating spinal motoneurons sustain functional sparing in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
Giusto E; Codrich M; de Leo G; Francardo V; Coradazzi M; Parenti R; Gulisano M; Vicario N; Gulino R; Leanza G
J Comp Neurol; 2020 Feb; 528(2):231-243. PubMed ID: 31364764
[TBL] [Abstract][Full Text] [Related]
28. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1
Bonifacino T; Provenzano F; Gallia E; Ravera S; Torazza C; Bossi S; Ferrando S; Puliti A; Van Den Bosch L; Bonanno G; Milanese M
Neurobiol Dis; 2019 Sep; 129():79-92. PubMed ID: 31102766
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic effects of dl-3-n-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis.
Feng XH; Yuan W; Peng Y; Liu MS; Cui LY
Chin Med J (Engl); 2012 May; 125(10):1760-6. PubMed ID: 22800896
[TBL] [Abstract][Full Text] [Related]
30. Androgen receptor antagonism accelerates disease onset in the SOD1
McLeod VM; Lau CL; Chiam MDF; Rupasinghe TW; Roessner U; Djouma E; Boon WC; Turner BJ
Br J Pharmacol; 2019 Jul; 176(13):2111-2130. PubMed ID: 30849180
[TBL] [Abstract][Full Text] [Related]
31. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1
Granucci EJ; Griciuc A; Mueller KA; Mills AN; Le H; Dios AM; McGinty D; Pereira J; Elmaleh D; Berry JD; Paganoni S; Cudkowicz ME; Tanzi RE; Sadri-Vakili G
Sci Rep; 2019 Nov; 9(1):17728. PubMed ID: 31776380
[TBL] [Abstract][Full Text] [Related]
32. Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis.
Apolloni S; Fabbrizio P; Parisi C; Amadio S; Volonté C
Mol Neurobiol; 2016 Jan; 53(1):518-531. PubMed ID: 25482048
[TBL] [Abstract][Full Text] [Related]
33. "Preconditioning" with latrepirdine, an adenosine 5'-monophosphate-activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice.
Coughlan KS; Mitchem MR; Hogg MC; Prehn JH
Neurobiol Aging; 2015 Feb; 36(2):1140-50. PubMed ID: 25443289
[TBL] [Abstract][Full Text] [Related]
34. Effect of thymic stimulation of CD4+ T cell expansion on disease onset and progression in mutant SOD1 mice.
Sheean RK; Weston RH; Perera ND; D'Amico A; Nutt SL; Turner BJ
J Neuroinflammation; 2015 Feb; 12():40. PubMed ID: 25889790
[TBL] [Abstract][Full Text] [Related]
35. Serial in vivo imaging of transplanted allogeneic neural stem cell survival in a mouse model of amyotrophic lateral sclerosis.
Srivastava AK; Gross SK; Almad AA; Bulte CA; Maragakis NJ; Bulte JWM
Exp Neurol; 2017 Mar; 289():96-102. PubMed ID: 28038988
[TBL] [Abstract][Full Text] [Related]
36. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
Yoo YE; Ko CP
Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
[TBL] [Abstract][Full Text] [Related]
38. Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1(G93A) mice model of ALS.
Rabinovich-Nikitin I; Ezra A; Barbiro B; Rabinovich-Toidman P; Solomon B
J Neuroinflammation; 2016 May; 13(1):123. PubMed ID: 27230771
[TBL] [Abstract][Full Text] [Related]
39. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.
Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C
Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725
[TBL] [Abstract][Full Text] [Related]
40. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice.
Kaneb HM; Sharp PS; Rahmani-Kondori N; Wells DJ
PLoS One; 2011; 6(9):e24189. PubMed ID: 21909419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
